Table 3.
Balance of Baseline Characteristics and Effective Sample Size Following Matching of Patients on a Prior Prophylactic Regimen from the B-LONG Weekly Dose-Adjusted and Interval-Adjusted Prophylaxis Groups and Group 1 of PROLONG-9FP
| Prior to Matching | rFIXFc Adjusted Population | |||
|---|---|---|---|---|
| rIX-FP (n=40) | rFIXFc Unadjusted Population (n=45)a | Estimate (SD) | ESS, n (%) | |
| Mean (SD) age, years | 31.6 (15.2) | 34.2 (14.8) | 31.6 (15.2) | 41.7 (92.6) |
| Mean (SD) weight, kg | 69.6 (14.4) | 76.8 (17.4) | 69.6 (14.4) | 37.4 (83.1) |
| Mean (SD) prior bleeds | 3.4 (3.8) | 4.8 (5.9) | 3.4 (3.8) | 37.9 (92.4) |
| Proportion of white patients, % | 83 | 67 | 83 | 40.2 (89.3) |
| Final adjusted population | ||||
| Mean (SD) age, years | – | – | 31.6 (15.2) | 25.6 (62.6) |
| Mean (SD) weight, kg | – | – | 69.6 (14.4) | |
| Mean (SD) prior bleeds | – | – | 3.4 (3.8) | |
| Proportion of white patients, % | – | – | 83 | |
Note: aData missing for ABR and treatment duration (n=3).
Abbreviations: ABR, annualized bleeding rate; ESS, effective sample size; rIX-FP, rFIX albumin fusion protein; rFIXFc recombinant factor IX-Fc fusion protein; SD standard deviation.